METHYL-PHENIDYLACETATE HYDROCHLORIDE (RITALIN) IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS
Abstract
In this group of 50 chronic schizophrenic patients, half of whom received Ritalin and half an identical appearing placebo the Ritalin was without demonstrable effect. Six of those on Ritalin showed a decrease in appetite, abdominal discomfort, and weight loss during the test.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).